Valuation dashboard for Align Technology, Inc. (ALGN) with P/E 23.97, P/B 2.72, EV/EBITDA 14.3 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Align Technology, Inc. is a medical technology enterprise that develops, produces, and markets its leading products: Invisalign transparent dental aligners and iTero digital intraoral scanners, along with related services. These offerings serve a wide range of dental professionals, including orthodontists, general dentists, and those specializing in restorative and cosmetic dentistry.
Where would it trade at its usual multiples?
Versus its usual multiples: cheap · Current P/E 24.0× · Multiples range: $211.15 · $353.56.
At the decade median (51.4×) $354 (+114%); at its sector median (30.7×) $211 (+28%). Implied price from applying the reference multiples to today's earnings (or book value, or FFO) per share. Not a fair value: it is where the stock would trade at its usual multiples.
Analysis Summary
Align Technology, Inc. reported revenue of $4.03B in the most recent fiscal year, growing at a 5-year CAGR of 10.3%. Net income reached $410.4M, with a -25.4% 5-year CAGR.
Trailing-twelve-month margins: gross margin 67.6%, operating margin 15.0%, net margin 11.8%.
At $164.90 (closing price, November 4, 2026), ALGN trades at a P/E of 23.97 and an ROE of 11.76%. Market capitalisation stands at $11.7B, placing it among large-cap names.
Balance sheet quality for ALGN: debt-to-equity ratio of 0.03, current ratio of 1.42 over the last 12 months. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 23.97 |
| Price / Book | 2.72 |
| EV / EBITDA | 14.3 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ALGN | Align Technology, Inc. | $11.7B | 23.97 | 2.72 | 11.8% |
| XRAY | DENTSPLY SIRONA Inc. | $2.1B | 1.57 | -39.8% | |
| NVST | Envista Holdings Corp | $4.4B | 7.04 | 1.42 | 20.5% |
| ABT | Abbott Laboratories | $199.9B | 42.78 | 3.07 | 8.5% |
| MDT | Medtronic Plc | $134.3B | 25.85 | 2.67 | 10.6% |
| SYK | Stryker Corporation | $130.3B | 36.17 | 5.47 | 15.6% |
| 0Y6X.L | Medtronic Plc | $124.4B | 23.33 | 2.43 | 10.6% |
| 0R2S.L | Stryker Corporation | $111.1B | 31.57 | 4.91 | 16.4% |
Price
| Price | $164.90 (closing price, November 4, 2026) |
| Market Cap | $11.7B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | 11.76% |
| Return on Invested Capital | 10.35% |
| Return on Assets | 7.54% |
| Gross Margin | 67.58% |
| Operating Margin | 15.02% |
| Net Margin | 11.83% |
Related companies: XRAY · NVST · ABT · MDT · SYK · 0Y6X.L · 0R2S.L · BSX
Explore sector: Healthcare · Medical - Devices
More sections of ALGN: Overview · Financials · Estimates · Technical · Ownership
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks